The purpose of the trial is to determine if extended-release dipyridamole + aspirin \[Aggrenox, Asasa ntin\] is superior to clopidogrel \[Plavix\], and if telmisartan \[Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan\] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one.
25mg aspirin, 200 mg dipyridamole
25mg aspirin, 200 mg dipyridamole
placebo
placebo
80 mg micardis
80 mg micardis
placebo
placebo
75 mg clopidogrel
75 mg clopidogrel
placebo
placebo
Capital Federal, Argentina
Capital Federal, Argentina
Capital Federal, Argentina
Capital Federal, Argentina
Capital Federal, Argentina
Rosario, Santa Fe, Argentina
Santa Fe, Argentina